APLS - Apellis Pharmaceuticals: PEGASUS Trial Confirms Pegcetacoplan's Efficacy Over Soliris In PNH Patients
Apellis Pharmaceuticals (APLS) reported positive phase 3 results of pegcetacoplan (APL-2) in PNH patients. Pegcetacoplan, the company's C3 inhibitor, managed to beat Alexion Pharmaceuticals' (ALXN) eculizumab (Soliris) on the primary endpoint and to show positive trends on multiple secondary endpoints. Safety and tolerability were not perfect, but I think Apellis has a competitive drug and that it can at least capture the underserved PNH patient population - those with an inadequate response to Soliris. However, the PNH treatment landscape is evolving, and Alexion and other potential competitors are not too far